Immunosuppression and Bactrim


Immunosuppression Symptoms and Causes

We are sorry, but no medical information on this topic currently exists in our database. Our articles are updated often, please revisit soon.

Check out the latest treatments for immunosuppression

immunosuppression treatment research studies

Bactrim clinical trials, surveys and public health registries

Find Drug Side Effect reports

Bactrim Side Effects

Pyrexia (115)
Rash (109)
Nausea (99)
Stevens-johnson Syndrome (88)
Vomiting (71)
Renal Failure Acute (69)
Fatigue (62)
Headache (60)
Pruritus (58)
Asthenia (57)
Diarrhoea (53)
Pain (48)
Dyspnoea (48)
Chills (44)
Erythema (37)
Urticaria (37)
Abdominal Pain (35)
Hyperkalaemia (35)
Dizziness (34)
Alanine Aminotransferase Increased (32)
Toxic Epidermal Necrolysis (32)
Arthralgia (32)
Myalgia (31)
Thrombocytopenia (30)
Rash Erythematous (28)
Jaundice (28)
Aspartate Aminotransferase Increased (27)
Dehydration (27)
Blood Creatinine Increased (25)
Renal Failure (25)
Neutropenia (24)
Platelet Count Decreased (23)
Blister (22)
Hypersensitivity (22)
Insomnia (22)
Hypotension (21)
Pain In Extremity (20)
Anaemia (20)
Pneumonia (20)
Rash Pruritic (20)
Confusional State (20)
Cough (19)
Hyponatraemia (19)
Decreased Appetite (19)
Hyperhidrosis (18)
Skin Exfoliation (17)
Swelling Face (17)
White Blood Cell Count Decreased (17)
Rash Maculo-papular (17)
Pulmonary Embolism (17)

➢ More

Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)

Recent Reviews

After taking Bactrim for 1 week and seeing no improvement in my impetigo my MD prescribed 2 tablets twice a day. I woke up that night with the worst headache of my life. (I don't get headaches!) My neck was stiff and my shoulders and back hurt so bad

Bactrim made my wbc dropp badly. I had all sorts of aches and pains. Since then I developped sensitivity to everything, I can't take any kind of drug. Carole have you found something that helped with the chemical sensiticity?

Can bactrim be used 2 treat cellulitis

Can Bactrim change your menstral cycle

I am the person who wrote about my 10 year old daughter. Can Bactrim also have the symptoms of palpitations, body aches, stomach aches, trouble sleeping and mood changes?

I had a bad reaction to Bactrim in 1987-I still don't have my health back. Now I have asthma and sinusitis, chemical sensitivities and immune problems. Don't take this killer drug under ANY circumstances.

I took Bactrim for an infected Bartholin Cyst for four days. On the third day I started thinking very disturbing thoughts that were almost like they were not my own. It made me terrified of being alone with my son, afraid that I would hurt him. At

I took my 10 year old daughter to the ER last Sunday, over a week ago, and they diagnosed her with Urinary Tract Infection. They prescribed Sulfameth / Trimeth or Bactrim. Since taking the medicine, she has had some symptoms she cannot explain sinc

I took this medication it made me sicker than ever, i woke up with stiff muscle ,chill in back bone , shacking , faintness, dizziness

I'm going through it now, I have so many hives all over me that some parts of me look like I have sunburn. I facilate between thinking "just shoot me know" and "I hope this ends soon, I can get through this." I i

Immunosuppression Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole
Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Cotrimoxazole;   Drug: Placebo
Outcome Measures: Evaluate the efficacy of oral cotrimoxazole versus placebo in idiopathic pulmonary fibrosis (IPF).;   Evaluate the safety of oral cotrimoxazole versus placebo in IPF.;   Evaluate the effect of cotrimoxazole on the natural history of Pneumocystis colonization in patients with IPF.;   Identify the effects of cotrimoxazole systemic level of inflammatory activity in patients with IPF.
2 Recruiting Pharmacokinetic Parameters of Co-trimoxazole
Condition: Tuberculosis
Intervention: Drug: co-trimoxazole
Outcome Measures: AUC;   Determination of the AUC/MIC and T>MIC;   Validating DBS analysis
3 Recruiting Co-trimoxazole as Maintenance Therapy for Meliodosis
Condition: Meliodosis
Interventions: Drug: Co-trimoxazole 12;   Drug: Co-trimoxazole 20
Outcome Measures: 1-year non relapse rate;   Clinical Recurrence;   Treatment failure;   Mortality;   Adverse Drug Reactions;   Drug compliance
4 Recruiting Cotrimoxazole Versus Vancomycin for Invasive Methicillin-resistant Staphylococcus Aureus Infections
Conditions: Staphylococcal Infections;   Meningitis;   Sepsis;   Pneumonia
Interventions: Drug: Cotrimoxazole;   Drug: Vancomycin
Outcome Measures: Primary efficacy: Improved or cure with or without antibiotic modifications, defined as: survival at 7 days post randomization with resolution of fever and resolution of hypotension;   Primary safety: 30-day all cause mortality;   Improved or cure without antibiotic modifications;   Modification of the anti-staphylococcal treatment within 1 week of treatment onset for perceived failure of therapy;   Survival at 7 days post randomization without the need for modification of the anti-staphylococcal antibiotic;   Bacteriological failure, defined as persistent isolation of Staphylococcus aureus with the same phenotype 7 days after or more after treatment onset;   Need for surgical intervention or other invasive procedures;   Need for central catheter removal;   Persistent bacteremia;   All-cause mortality in ICU and in-hospital;   Adverse events;   Durations of fever, assigned antibiotic treatment, mechanical ventilation, ICU and hospital stay;   Resistance development
5 Unknown  Influence of Trimethoprim-Sulfamethoxazole for the Recurrence of Ocular Toxoplasmosis
Condition: Ocular Toxoplasmosis
Intervention: Drug: Trimethoprim-Sulfamethoxazole
Outcome Measure: Incidence of episodes of recurrent chorioretinitis by toxoplasmosis in the follow up of 12 months.
6 Recruiting Randomized Clinical Trial to Compare a Regimen of Trimethoprim-sulfamethoxazole Plus Rifampicin With a Regimen of Linezolid in the Treatment of Methicillin-Resistant Staphylococcus Aureus (MRSA) Infection
Condition: MRSA Infection
Interventions: Drug: trimethoprim-sulfamethoxazole (TMP-SMX);   Drug: Linezolid;   Drug: Rifampicin
Outcome Measures: Bacteriological and clinical cure;   Treatment costs
7 Unknown  Cotrimoxazole Prophylaxis Cessation Study Among Stabilized HIV-Infected Adult Patients on HAART in Entebbe, Uganda
Condition: HIV Infections
Interventions: Drug: cotrimoxazole;   Drug: Placebo
Outcome Measures: all-cause morbidity such as pneumonia or malaria (presumptive and definitive diagnosis);   sub-clinical laboratory abnormalities (such as neutropenia) and serious adverse events (such as death)
8 Unknown  Antibiotics Versus Placebo in the Treatment of Abscesses in the Emergency Department
Condition: Abscess
Interventions: Drug: Trimethoprim-sulfamethoxazole;   Drug: Sugar pill
Outcome Measures: The objective of this study is to compare clinical indicators of abscess resolution for two different treatment methods: 1) incision and drainage plus placebo (I&D/P) and 2) incision and drainage plus trimethoprim-sulfamethoxazole (TMP-SMX) (I&D/T-S).;   Comparison of medication adverse effect profiles between the groups, comparison of outcomes between MRSA isolates versus other pathogens between the groups, and analysis of interrater reliability of physical exam findings for a subgroup of patients.
9 Recruiting Daily Trimethoprim-sulfamethoxazole or Weekly Chloroquine Among Adults on ART in Blantyre, Malawi
Condition: HIV
Interventions: Drug: Standard of Care prophylaxis;   Drug: Chloroquine (CQ) prophylaxis
Outcome Measures: Severe events;   HIV viral load;   CD4 cell count;   WHO HIV stage 2, 3, 4 illness;   Bacterial infections and malaria;   Adverse events greater than or equal to Grade 3 that are related to the study product
10 Recruiting Impact of TMP-SMX Prophylaxis on Malaria Infection and Immunity in Children in Uganda
Condition: Malaria
Intervention: Drug: TMP-SMX
Outcome Measure: Primary outcome is to measure the incidence rate (number of new malaria parasitemia episodes) in HUE children on SOC versus EP TMP-SMX prophylaxs.
11 Recruiting Study to Improve Survival Among HIV-Exposed Infants in Botswana
Conditions: HIV Infections;   Neutropenia;   Anemia
Interventions: Drug: cotrimoxazole prophylaxis;   Drug: cotrimoxazole placebo;   Behavioral: exclusive breastfeeding until 6 months of age;   Behavioral: breastfeeding for 12 months
Outcome Measures: Survival;   HIV-free Survival;   Safety of CTX prophylaxis;   Morbidity and mortality
12 Not yet recruiting Efficacy of Antifolates Against Malaria in HIV-infected Pregnant Women and the Emergence of Induced Resistance in Plasmodium Falciparum
Conditions: Malaria in Pregnancy;   HIV Infection
Interventions: Drug: cotrimoxazole daily prophylaxis;   Drug: sulphadoxine-pyrimethamine
Outcome Measures: placental parasitaemia;   observance CTM prophylaxis;   occurrence of specific events related to the effectiveness of CTM prophylaxis and IPT-SP;   occurence of adverse events
13 Recruiting Uncomplicated Skin and Soft Tissue Infections Caused by Community-Associated Methicillin-Resistant Staphylococcus Aureus
Condition: Staphylococcal Infection
Interventions: Drug: Clindamycin;   Drug: Trimethoprim-sulfamethoxazole (TS);   Drug: Placebo
Outcome Measures: Clinical cure, defined as absence of clinical failure.;   Efficacy outcome: clinical cure of recurrences or relapses of SSTI.;   Safety outcomes: adverse events; and adverse events that are treatment limiting.
14 Recruiting The SCOUT Study: Short Course Therapy for Urinary Tract Infections in Children
Condition: Urinary Tract Infections
Interventions: Drug: Trimethoprim sulfamethoxazole, amoxicillin-clavulanate, cefixime, or cephalexin;   Drug: Placebo
Outcome Measures: Occurrence of treatment failures between short-course and standard-course therapies;   Occurrence of recurrent infections;   Occurrence of colonization with antimicrobial resistant bacteria;   Occurrence of asymptomatic bacteriuria;   Occurrence of clinical symptoms;   Occurrence of positive urine cultures
15 Recruiting A Pharmacokinetic and Pharmacogenetic Study in Patients Receiving Sulfamethoxazole-trimethoprim Therapy
Condition: Pneumocystis Jiroveci Pneumonia
Outcome Measure: High performance liquid chromatography for drug plasma concentration
16 Not yet recruiting New Mexico Honey Wound Treatment Research Study
Condition: Community-acquired MRSA Infection
Interventions: Drug: New Mexico Honey;   Drug: Bactrim DS
Outcome Measure: Size of lesion at day 7
17 Recruiting VSL#3 and Spontaneous Bacterial Peritonitis
Condition: Decompensated Cirrhosis With Ascites.
Interventions: Drug: cotrimoxazole;   Drug: VSL#3 active;   Drug: VSL#3 placebo
Outcome Measures: Liver-related mortality and liver related morbidity;   Incidence of SBP, variceal bleeding, any non-SBP sepsis (e.g. pneumonia, urinary tract infection), clinical episodes of encephalopathy and the incidence of C. difficile infection.
18 Recruiting Antibiotic Prophylaxis in Children With Pyelonephritis
Condition: Pyelonephritis
Interventions: Drug: Trimethoprim Sulfamethoxazole;   Drug: placebo
Outcome Measures: To determine whether antibiotic prophylaxis prevents recurrent urinary tract infections by assessing if there is a decreased incidence of urinary tract infections.;   To determine whether antibiotic prophylaxis prevents long-term renal scarring by assessing results of DMSA scans to look at long term renal scarring.;   To determine whether recurrent infections and involvement with the medical system impacts quality of life by assessing how this medical condition affects children using standardized quality of life questionnaires.
19 Recruiting Efficacy and Safety Study of Antibiotic Treatment to Treat Hip Prosthetic Joint Infection
Condition: Hip Prosthetic Joint Infection
Outcome Measures: Clinical cure rate;   Cure rate
20 Recruiting Efficacy of Fosfomycin-Trometamol in Urinary Tract Infection Prophylaxis After Kidney Transplantation
Conditions: Urinary Tract Infection;   Asymptomatic Bacteriuria;   Allograft Rejection;   Microbiologic Resistance;   Hospitalization
Interventions: Drug: Fosfomycin-Trometamol;   Drug: Sulfamethoxazole trimethoprim
Outcome Measures: Urinary tract infection incidence in the first six months after kidney transplantation;   Complications related to the intervention, including rate of microbiological resistance.